Tallying venture capital investments aplenty last year, Aduro Biotech Inc. chalked up more in a series D preferred stock financing of $51.4 million for its immuno-oncology pipeline, an amount that brings the total haul for the Berkeley, Calif.-based firm in 2014 to $106.4 million.